QTX-3034 is under clinical development by Quanta Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QTX-3034’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QTX-3034 overview
QTX3034 is under development for the treatment of solid tumors including pancreatic cancer, colorectal cancer, non-small cell lung cancer, and endometrial cancer. It is administered through oral route. The drug candidate acts by targeting KRAS G12D mutations.
Quanta Therapeutics overview
Quanta Therapeutics is a biopharmaceutical company focused on direct approaches targeting the protein interactions key to oncogenic RAS activity. Quanta Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of QTX-3034’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
